🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/08/2017 | 156,88 | 156,93 | 152,25 | 153,27 | -1,80% | 2,98% | 943.400 |
| 24/08/2017 | 153,60 | 156,63 | 151,10 | 156,08 | +1,85% | 3,60% | 1.148.700 |
| 23/08/2017 | 154,46 | 154,90 | 152,05 | 153,25 | -1,43% | 1,85% | 989.400 |
| 22/08/2017 | 149,19 | 155,92 | 149,19 | 155,48 | +4,34% | 4,51% | 1.659.700 |
| 21/08/2017 | 148,00 | 150,26 | 147,42 | 149,01 | +0,59% | 1,92% | 1.090.100 |
| 18/08/2017 | 147,65 | 150,11 | 147,18 | 148,13 | -0,28% | 1,98% | 887.000 |
| 17/08/2017 | 150,93 | 152,41 | 148,52 | 148,54 | -1,87% | 2,58% | 1.019.200 |
| 16/08/2017 | 152,79 | 153,26 | 150,31 | 151,37 | -0,88% | 1,93% | 913.400 |
| 15/08/2017 | 154,45 | 155,28 | 152,55 | 152,72 | -1,15% | 1,77% | 734.900 |
| 14/08/2017 | 154,52 | 155,87 | 153,54 | 154,49 | +0,46% | 1,51% | 1.081.800 |
| 11/08/2017 | 149,35 | 154,08 | 149,02 | 153,78 | +3,53% | 3,39% | 1.551.500 |
| 10/08/2017 | 152,01 | 152,04 | 148,50 | 148,54 | -2,65% | 2,33% | 1.302.800 |
| 09/08/2017 | 153,02 | 155,09 | 152,19 | 152,58 | -0,44% | 1,90% | 1.038.000 |
| 08/08/2017 | 156,12 | 156,55 | 152,90 | 153,26 | -2,05% | 2,34% | 892.900 |
| 07/08/2017 | 152,60 | 156,63 | 152,60 | 156,47 | +1,25% | 2,64% | 926.300 |
| 04/08/2017 | 154,68 | 155,17 | 153,01 | 154,54 | +0,33% | 1,40% | 807.800 |
| 03/08/2017 | 155,72 | 157,27 | 152,26 | 154,03 | -2,23% | 3,22% | 1.407.100 |
| 02/08/2017 | 151,80 | 157,91 | 151,47 | 157,55 | +2,84% | 4,24% | 1.781.700 |
| 01/08/2017 | 153,03 | 154,07 | 150,64 | 153,20 | +0,91% | 2,24% | 1.621.100 |
| 31/07/2017 | 152,99 | 154,49 | 151,54 | 151,82 | -1,51% | 1,93% | 2.972.700 |
| 28/07/2017 | 155,30 | 157,20 | 153,58 | 154,15 | -1,31% | 2,33% | 1.880.400 |
| 27/07/2017 | 160,88 | 163,32 | 153,50 | 156,19 | -4,42% | 6,10% | 3.918.900 |
| 26/07/2017 | 162,15 | 164,53 | 161,70 | 163,42 | +0,90% | 1,75% | 2.087.200 |
| 25/07/2017 | 166,94 | 167,86 | 161,72 | 161,97 | -2,49% | 3,68% | 2.424.100 |
| 24/07/2017 | 162,33 | 166,58 | 160,91 | 166,11 | +1,80% | 3,49% | 2.444.500 |
| 21/07/2017 | 158,14 | 163,64 | 156,53 | 163,17 | +2,41% | 4,50% | 3.176.400 |
| 20/07/2017 | 159,94 | 161,76 | 157,25 | 159,33 | -0,23% | 2,82% | 4.927.400 |
| 19/07/2017 | 161,80 | 167,00 | 158,88 | 159,69 | +20,83% | 5,02% | 16.800.100 |
| 18/07/2017 | 129,21 | 132,30 | 127,67 | 132,16 | +2,28% | 3,58% | 3.311.600 |
| 17/07/2017 | 130,44 | 132,05 | 128,26 | 129,21 | -1,36% | 2,91% | 1.136.200 |